Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Abstract Background The Valsartan Heart Failure Trial (Val‐HeFT) is the first large‐scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and
determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases …

Background: To investigate the role of persistent angiotensin activity despite
angiotensinconverting enzyme inhibitor therapy in the progression of heart failure, the …

Background. Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Although a cornerstone in the treatment of heart failure, angiotensin-converting enzyme
inhibitors are under-used, partly due to side effects. If proven at least similarly efficacious to …

Angiotensin II receptor blockers (ARBs) are the most recent class of anti‐hypertensive drug
to enter clinical use for chronic heart failure (CHF). In the landmark Valsartan Heart Failure …

Heart failure is the only major cardiovascular disease with an incidence and prevalence that
continue to increase in the developed world. Early identification and correct treatment of the …

Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …